AstraZeneca's Bevespi Aerosphere Gets EU Marketing Recommendation
October 19 2018 - 08:51AM
Dow Jones News
By Adria Calatayud
AstraZeneca PLC (AZN.LN) said Friday that the EU drug
regulator's Committee for Medicinal Products for Human Use has
recommended marketing authorization for Bevespi Aerosphere, an
inhaler for treatment of chronic obstructive pulmonary disease.
The recommendation from the European Medicines Agency committee
is based on the company's phase 3 pinnacle program, which
demonstrated the efficacy and safety of the inhaler, the
pharmaceutical company said.
Bevespi Aerosphere is approved in the U.S., Canada and Australia
as a dual bronchodilator for the long-term maintenance treatment of
chronic obstructive pulmonary disease, AstraZeneca said.
Shares at 1216 GMT were up 0.8% at 5,927 pence.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
October 19, 2018 08:36 ET (12:36 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024